Longleaf Partners Fund exits BIO
Seeking Alpha News (Mon, 13-Jul 10:35 AM ET)
Bio-Rad to Participate in Upcoming Investor Conferences
Business Wire (Fri, 8-May 9:00 AM ET)
Bio-Rad Reports First-Quarter 2026 Financial Results
Business Wire (Thu, 30-Apr 4:15 PM ET)
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Bio-Rad Laboratories Class A trades on the NYSE stock market under the symbol BIO.
As of July 17, 2026, BIO stock price climbed to $301.49 with 39,887 million shares trading.
BIO has a beta of 0.86, meaning it tends to be less sensitive to market movements. BIO has a correlation of 0.06 to the broad based SPY ETF.
BIO has a market cap of $8.13 billion. This is considered a Mid Cap stock.
Last quarter Bio-Rad Laboratories Class A reported $592 million in Revenue and $1.89 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$.25.
In the last 3 years, BIO traded as high as $431.79 and as low as $211.43.
The top ETF exchange traded funds that BIO belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.
BIO has outperformed the market in the last year with a price return of +21.9% while the SPY ETF gained +20.6%. However, in the short term, BIO had mixed performance relative to the market. It has underperformed in the last 3 months, returning +3.6% vs +6.5% return in SPY. But in the last 2 weeks, BIO shares have fared better than the market returning +1.6% compared to SPY +0.1%.
BIO support price is $294.02 and resistance is $307.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIO shares will trade within this expected range on the day.
